April 2, 2025- ADDISON, TX – Solenic Medical Inc., a pioneering medical device company focused on non-invasive solutions for infected metallic implants, today announced a significant achievement in its mission. The company has successfully treated its first patient as part of its early feasibility clinical trial utilizing its groundbreaking, investigational Alternating Magnetic Field (AMF) technology.
This monumental step marks the culmination of a long developmental journey aimed at treating patients with implant-associated infections, particularly prosthetic joint infections (PJIs). Solenic’s patented AMF technology offers a non-invasive approach to eradicate biofilms on implant surfaces by generating heat, working in conjunction with standard antibiotic therapy.
This achievement offers the promise of improved patient outcomes by potentially reducing the need for risky and expensive revision surgeries. The early feasibility study is evaluating the safety of the Sola2 AMF Knee System in adult patients with a suspected knee implant infection undergoing surgical debridement, antibiotics, and implant retention (DAIR).
“This novel technology has the potential to become an essential tool for management and possibly prevention of joint replacement infections.” said Dr. Cyrus Abbaschian M.D., Orthopaedic Surgeon who perform the procedure at Medical City Plano, in Plano, TX. This milestone underscores Solenic’s commitment to transforming the standard of care and improving the lives of patients facing this debilitating complication. “We are thrilled to reach this critical milestone and begin demonstrating the clinical potential of our AMF technology,” said James Lancaster, CEO of Solenic Medical.
The early feasibility trial is a key step in establishing the safety and effectiveness of AMF therapy in a clinical setting and lays the groundwork for future pivotal studies.
About Solenic Medical
Solenic Medical, Inc. is a medical device company developing an innovative non-invasive treatment for infected metallic implants in the body. Using technology invented at the University of Texas Southwestern, Solenic is leveraging the unique properties of alternating magnetic fields (AMF) generated by external coils to reduce, and possibly eradicate, the biofilm on the surface of metallic implants. This non-invasive, non-contact treatment addresses a major complication frequently associated with various surgeries such as knee and hip replacements, and orthopedic trauma cases requiring plates, rods, and/or nails. The technology is particularly important and timely given the rise in the aging population, longer life expectancy, and the rapid increase in the number of orthopedic procedures being performed every year. Solenic's AMF technology has been designated a Breakthrough Device by the U.S. FDA. It has the potential to completely replace the costly and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Solenic Medical, Inc. is a VIC Technology Venture Development™ portfolio company.